Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1974640 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $134.17Day −0.08%Mkt cap $8.1B1Y +238.3%Off 52W high −0.2%Vol (1Y) 71.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 757 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest6.8% of sh out |
| Days to cover2.4d |
| 13F net flow (QoQ)+12.38% |
| Top-10 13F concentration61.0% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$274.6M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+77.8% |
| 1Y+238.3% |
| 3Y+546.6% |
| Since incept. (ann.)+83.4% |
Total return through 2026-07-28 · series begins 2023-07-14. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)71.1% |
| Ann. volatility (3Y)71.6% |
| Sharpe (1Y)2.07 |
| Sharpe (3Y)1.21 |
| Max drawdown (1Y)−24.6% |
| Max drawdown (3Y)−58.8% |
| Beta (3Y vs SPY)0.35 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.3M | $867M | — | +140.2% |
| FMR LLC | 9.3M | $780M | — | +12.6% |
| Venrock Adviser, LLC | 8.5M | $715M | — | +0.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 4.4M | $368M | — | −7.8% |
| BlackRock, Inc. | 4.1M | $344M | — | +8.0% |
| RTW INVESTMENTS, LP | 2.8M | $234M | — | +2.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $211M | — | new |
| JANUS HENDERSON GROUP PLC | 2.4M | $199M | — | +14.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (79,061,223) exceed the latest reported shares-outstanding count (60,690,820) by more than securities-lending double counting can explain (FINRA short interest 9,489,537 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$1.06 | — | — | — |
| 2025-09-30 | 2025-11-10 | −$1.11 | — | — | — |
| 2025-06-30 | 2025-08-11 | −$1.13 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.95 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
